Which drug is used for the treatment of anemia associated with renal failure?

RRB Nsg. Superintendent -29 April-2025 (shift-2nd)

Pharmacology

Easy

Appeared in: RRB Nsg. Superintendent -29 April-2025 (shift-2nd)

Explanation

Chronic renal failure leads to decreased production of the hormone erythropoietin by the kidneys.
Erythropoietin is essential for stimulating the bone marrow to produce red blood cells (erythropoiesis).
Administering a synthetic form of erythropoietin directly addresses this hormonal deficiency, making it the primary treatment for anemia of renal failure.
This therapy increases hemoglobin and hematocrit levels, reducing the need for blood transfusions and improving the patient's quality of life.

Option B: Interleukins are cytokines that regulate immune responses and are used in cancer therapy or for immune modulation. They do not stimulate red blood cell production.
Option C: Ferrous sulphate is an oral iron supplement. While essential for hemoglobin synthesis, it cannot initiate red blood cell production in the absence of erythropoietin stimulation. It is an adjunct, not the primary treatment.
Option D: Iron dextran is a parenteral (injectable) iron supplement. Similar to oral iron, it provides the building blocks for hemoglobin but does not address the root cause of anemia in renal failure, which is the lack of hormonal stimulation from erythropoietin.

Visual 1: Diagram: A flowchart showing how kidney failure leads to decreased erythropoietin, which causes anemia, and how ESA therapy intervenes to stimulate the bone marrow.
Visual 2: Infographic: A comparison table showing the mechanisms of action for Erythropoietin vs. Iron Supplements in treating anemia.

Clinical Relevance

Nursing practice connection: Knowing Pharmacological treatment for anemia associated with chronic kidney disease helps nurses interpret findings accurately and avoid errors in routine assessment, medication administration, and patient teaching.
Nurses administering erythropoietin must closely monitor blood pressure, as hypertension is a common and serious side effect.
Monitoring hemoglobin levels is crucial to avoid raising them too quickly or too high (target is typically 10-11 g/dL), which increases the risk of thrombosis, stroke, and heart attack.
Patient education should include the importance of adhering to both erythropoietin and any prescribed iron supplements for the treatment to be effective.

How to Approach the Question

First, identify the core pathophysiology in the question: anemia specifically 'associated with renal failure'.
Recall the primary endocrine function of the kidneys related to blood production. The kidneys produce erythropoietin.
Reason that if the kidneys are failing, their ability to produce erythropoietin will be impaired.
Evaluate the options based on this pathophysiology. The most logical treatment would be to replace the missing hormone.
Erythropoietin is listed as an option and directly replaces the deficient hormone.
Consider the other options: Iron (ferrous sulphate, iron dextran) is needed for RBC production but doesn't stimulate it. Interleukin is an immune modulator. Therefore, erythropoietin is the most direct and primary treatment.

Concept Tested & Keywords

Concept Tested: Pharmacological treatment for anemia associated with chronic kidney disease.
Stem keywords: anemia, renal failure, drug, treatment
Lead-in keywords: Which
Negative lead-in flag: false

QpgmO98YcWFh6MJyOZa5Sb